These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Constantinidou A; Smith I Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286 [TBL] [Abstract][Full Text] [Related]
3. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921 [TBL] [Abstract][Full Text] [Related]
4. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. von Minckwitz G; Loibl S; Maisch A; Untch M Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282 [TBL] [Abstract][Full Text] [Related]
5. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy and targeted therapies: a promising strategy. Metzger-Filho O; de Azambuja E J Natl Cancer Inst Monogr; 2011; 2011(43):116-9. PubMed ID: 22043056 [TBL] [Abstract][Full Text] [Related]
7. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A Breast J; 2010; 16(1):66-72. PubMed ID: 19889170 [TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Baselga J; Perez EA; Pienkowski T; Bell R Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734 [TBL] [Abstract][Full Text] [Related]
10. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566 [TBL] [Abstract][Full Text] [Related]
11. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263 [TBL] [Abstract][Full Text] [Related]
12. Disease related indicators for a proper choice of adjuvant treatments. Hayes DF Breast; 2011 Oct; 20 Suppl 3():S162-4. PubMed ID: 22015287 [TBL] [Abstract][Full Text] [Related]
13. Targeting adjuvant chemotherapy: a good idea that needs to be proven! Hayes DF J Clin Oncol; 2012 Apr; 30(12):1264-7. PubMed ID: 22355050 [No Abstract] [Full Text] [Related]
14. Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288 [TBL] [Abstract][Full Text] [Related]
15. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab. Chan A; McGregor SR Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440 [TBL] [Abstract][Full Text] [Related]
17. [Update: adjuvant trastuzumab in HER2 positive breast cancer]. Tahover E; Sonnenblick A; Peretz T; Katz D Harefuah; 2012 Jan; 151(1):37-42, 61. PubMed ID: 22670500 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735 [TBL] [Abstract][Full Text] [Related]
19. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Megerdichian C; Olimpiadi Y; Hurvitz SA Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997 [TBL] [Abstract][Full Text] [Related]